Literature DB >> 11286044

New alternative agents in essential tremor therapy: double-blind placebo-controlled study of alprazolam and acetazolamide.

D I Gunal1, N Afşar, N Bekiroglu, S Aktan.   

Abstract

Propranolol and primidone are widely used, effective agents in essential tremor although they are not tolerated by all patients. In the present study, the effectiveness of alprazolam, a triazole analog of benzodiazapine class, and acetazolamide, a carbonic anhydrase inhibitor, were investigated as symptomatic treatments for essential tremor. We studied 22 patients with essential tremor in a double-blind, cross-over, placebo-controlled design. The patients received in random order alprazolam, acetazolamide, primidone and placebo for four weeks, each separated by a two-week washout period. The study demonstrated that alprazolam was superior to placebo and equipotent to primidone, whereas there was no statistically significant difference between acetazolamide and placebo. The mean effective daily dose of alprazolam was 0.75 mg and there was not any troublesome side effect reported by the patients on alprazolam. Alprazolam can be used as an alternative agent in elderly essential tremor patients who can not tolerate primidone or propranolol.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11286044     DOI: 10.1007/s100720070069

Source DB:  PubMed          Journal:  Neurol Sci        ISSN: 1590-1874            Impact factor:   3.307


  19 in total

Review 1.  Essential tremor.

Authors:  Joaquim Jos Ferreira; Cristina Sampaio
Journal:  BMJ Clin Evid       Date:  2007-05-01

Review 2.  Pharmacotherapy of essential tremor : an overview of existing and upcoming agents.

Authors:  Kelly E Lyons; Rajesh Pahwa
Journal:  CNS Drugs       Date:  2008       Impact factor: 5.749

3.  T-type calcium channel antagonists suppress tremor in two mouse models of essential tremor.

Authors:  Adrian Handforth; Gregg E Homanics; Douglas F Covey; Kathiresan Krishnan; Jae Yeol Lee; Kenji Sakimura; Fredricka C Martin; Arnulfo Quesada
Journal:  Neuropharmacology       Date:  2010-06-12       Impact factor: 5.250

4.  Update on treatment of essential tremor.

Authors:  Theresa A Zesiewicz; Jessica D Shaw; Kevin G Allison; Joseph S Staffetti; Michael S Okun; Kelly L Sullivan
Journal:  Curr Treat Options Neurol       Date:  2013-08       Impact factor: 3.598

Review 5.  Exploring the Potential of Small Molecule-Based Therapeutic Approaches for Targeting Trinucleotide Repeat Disorders.

Authors:  Arun Kumar Verma; Eshan Khan; Sonali R Bhagwat; Amit Kumar
Journal:  Mol Neurobiol       Date:  2019-08-09       Impact factor: 5.590

Review 6.  Pharmacological management of essential tremor.

Authors:  Reza Sadeghi; William G Ondo
Journal:  Drugs       Date:  2010-12-03       Impact factor: 9.546

Review 7.  Benefits and risks of pharmacological treatments for essential tremor.

Authors:  Kelly E Lyons; Rajesh Pahwa; Cynthia L Comella; Mahmood S Eisa; Rodger J Elble; Stanley Fahn; Joseph Jankovic; Jorge L Juncos; William C Koller; William G Ondo; Kapil D Sethi; Matthew B Stern; Caroline M Tanner; Ron Tintner; Ray L Watts
Journal:  Drug Saf       Date:  2003       Impact factor: 5.606

8.  Overview of essential tremor.

Authors:  Theresa A Zesiewicz; Abinaya Chari; Israt Jahan; Amber M Miller; Kelly L Sullivan
Journal:  Neuropsychiatr Dis Treat       Date:  2010-09-07       Impact factor: 2.570

Review 9.  Treatment of essential tremor: a systematic review of evidence and recommendations from the Italian Movement Disorders Association.

Authors:  Mario Zappia; Alberto Albanese; Elisa Bruno; Carlo Colosimo; Graziella Filippini; Paolo Martinelli; Alessandra Nicoletti; Graziella Quattrocchi; Giovanni Abbruzzese; Alfredo Berardelli; Roberta Allegra; Maria Stella Aniello; Antonio E Elia; Davide Martino; Daniela Murgia; Marina Picillo; Giovanna Squintani
Journal:  J Neurol       Date:  2012-08-11       Impact factor: 4.849

Review 10.  Fragile X-associated tremor/ataxia syndrome: clinical phenotype, diagnosis, and treatment.

Authors:  Maureen A Leehey
Journal:  J Investig Med       Date:  2009-12       Impact factor: 2.895

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.